mRNA-4359
Phase 2Recruiting 1 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors
Trial Timeline
Sep 1, 2022 → Feb 18, 2032
NCT ID
NCT05533697About mRNA-4359
mRNA-4359 is a phase 2 stage product being developed by Moderna for Advanced Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05533697. Target conditions include Advanced Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05533697 | Phase 2 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumors